Pivotal Study of Investigational 9-Valent HPV Vaccine Demonstrates Additional Protection Against HPV-Related Disease
Lyon, France (ots/PRNewswire) - - New 9-valent HPV vaccine prevented 97% of cervical, vaginal and vulvar pre-cancers caused by five additional HPV types - Immunogenicity non-inferior to GARDASIL for original four HPV types Lyon, 4 November 2013 - Sanofi Pasteur MSD reported today that Merck's investigational ...